Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe symbols : Adct save search
ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress
Published: 2023-05-11 (Crawled : 19:00) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: 0.83%
H: 7.02%
C: -0.41%
association trial therapeutics results
ADC Therapeutics to Host First Quarter 2023 Financial Results Conference Call on May 9, 2023
Published: 2023-05-02 (Crawled : 12:00) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: -0.51%
H: 0.26%
C: -2.56%
conference therapeutics financial results
ADC Therapeutics to Participate in February Investor Conferences
Published: 2023-02-01 (Crawled : 13:20) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: 1.57%
H: 5.68%
C: 5.01%
therapeutics
ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Published: 2023-01-04 (Crawled : 13:00) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: -3.34%
H: 2.02%
C: -0.58%
conference therapeutics
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
Published: 2022-12-19 (Crawled : 13:00) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: -0.92%
H: 0.31%
C: -5.59%
therapeutics financial
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting
Published: 2022-11-03 (Crawled : 14:00) - biospace.com/
GNMSF | $290.38 220
|
Health Technology
|
| O: -2.44%
H: 5.65%
C: 5.65%
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: -2.18%
H: 8.91%
C: 8.17%
GMAB | $28.67 1.2% 41K
|
Health Technology
|
| O: -1.73%
H: 4.51%
C: 3.15%
meeting therapeutics presentation
ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Published: 2022-09-16 (Crawled : 12:00) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: -1.29%
H: 3.35%
C: -2.23%
zynlonta treatment europe chmp therapeutics positive
ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
Published: 2022-08-09 (Crawled : 17:00) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: -2.24%
H: 2.67%
C: 1.27%
therapeutics results
ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories
Published: 2022-07-08 (Crawled : 09:00) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: -0.11%
H: 18.91%
C: 12.68%
zynlonta europe license therapeutics agreement international
ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
Published: 2022-06-10 (Crawled : 11:00) - biospace.com/
GNMSF | $290.38 220
|
Health Technology
|
| O: -4.41%
H: 3.01%
C: 0.79%
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: -4.98%
H: 0.0%
C: 0.0%
GMAB | $28.67 1.2% 41K
|
Health Technology
|
| O: -5.18%
H: 0.0%
C: 0.0%
trial therapeutics results phase 2
ADC Therapeutics to Present at the Jefferies Healthcare Conference
Published: 2022-06-01 (Crawled : 12:20) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: -6.54%
H: 1.46%
C: -4.52%
conference therapeutics
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
Published: 2022-05-09 (Crawled : 12:00) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: -3.94%
H: 1.1%
C: -28.08%
therapeutics results
ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
Published: 2022-05-04 (Crawled : 12:00) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: 1.27%
H: 4.35%
C: 2.51%
conference therapeutics
ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services
Published: 2022-04-04 (Crawled : 12:00) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: 0.07%
H: 8.09%
C: 1.01%
zynlonta services therapeutics
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021
Published: 2022-03-17 (Crawled : 13:00) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: -1.08%
H: 11.16%
C: 6.4%
therapeutics report
ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
Published: 2022-03-03 (Crawled : 12:30) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: 3.0%
H: 0.0%
C: -13.12%
financial results therapeutics report results
ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan
Published: 2022-01-18 (Crawled : 11:00) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: -8.09%
H: 2.66%
C: 0.06%
zynlonta license therapeutics corporation commercialization pharma
ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®
Published: 2021-10-29 (Crawled : 12:00) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: 0.24%
H: 1.01%
C: 0.66%
europe application
ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®
Published: 2021-09-13 (Crawled : 12:00) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: -0.22%
H: 3.07%
C: 1.2%
orphan drug europe drug therapeutics designation
ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
ADCT | $4.88 2.52% 77K
|
Health Technology
|
| O: -0.18%
H: 2.19%
C: 0.14%
approval
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.